<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">962994</article-id><article-id pub-id-type="pmc">2025153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Newlands</surname><given-names>E. S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Oon</surname><given-names>C. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>J. T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Elliott</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mould</surname><given-names>R. F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Topham</surname><given-names>C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Madden</surname><given-names>F. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Newton</surname><given-names>K. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Westbury</surname><given-names>G.</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><month>8</month><year>1976</year></pub-date><volume>34</volume><issue>2</issue><fpage>174</fpage><lpage>179</lpage><abstract><p>Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00305-0065.tif" xlink:title="scanned-page" xlink:role="174" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00305-0066.tif" xlink:title="scanned-page" xlink:role="175" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00305-0067.tif" xlink:title="scanned-page" xlink:role="176" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00305-0068.tif" xlink:title="scanned-page" xlink:role="177" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00305-0069.tif" xlink:title="scanned-page" xlink:role="178" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00305-0070.tif" xlink:title="scanned-page" xlink:role="179" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

